SynthesisNeurology2012
Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
Synthesis in Neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project.Journal of neurology · 2020Pooled it
- Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses: A Systematic Review and Meta-analysis.JAMA neurology · 2020Pooled it
- A systematic review and meta-analysis of strength training in individuals with multiple sclerosis or Parkinson disease.Medicine · 2015Pooled it
- Sex differences in the development, treatment, and prognosis of multiple sclerosis in Switzerland.Frontiers in neuroscience · 2026Article
- Pregnancy outcome in patients with multiple sclerosis: A retrospective study from single center in Benghazi, Libya.Current journal of neurology · 2025Article
- Sex impacts treatment decisions in multiple sclerosis.Journal of neurology · 2024Article
- Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Rubella virus infection in endothelial cells reduces angiogenesis via interferon beta-induced CXCL10.iScience · 2023Article
- Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate.Wiener medizinische Wochenschrift (1946) · 2022Article
- Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.Degenerative neurological and neuromuscular disease · 2022Review
- Treatment of Women with Multiple Sclerosis Planning Pregnancy.Current treatment options in neurology · 2021Review
- The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.The patient · 2020Article
- Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations.Journal of drug assessment · 2020Article
- Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden.Therapeutic advances in neurological disorders · 2020Article
- Sex effects across the lifespan in women with multiple sclerosis.Therapeutic advances in neurological disorders · 2020Review
- Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children.Neurology and therapy · 2018Review
- The Short and Long-Term Effects of Pregnancy on Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.Journal of clinical medicine · 2018Review
- Caring for Women with Multiple Sclerosis Across the Lifespan.Current neurology and neuroscience reports · 2018Review
- An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis.CNS drugs · 2018Review
- Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo systematically review the literature regarding safety of disease-modifying drug (DMD) use during pregnancy on perinatal and developmental outcomes in offspring of patients with multiple sclerosis (MS).
methodsA PubMed and EMBASE search up to February 2012 was conducted with a manual search of references from relevant articles. Selected studies were evaluated using internationally accepted criteria.
resultsFifteen studies identified 761 interferon β-, 97 glatiramer acetate-, and 35 natalizumab-exposed pregnancies. Study quality ranged from poor to good; no study was rated excellent. Small sample sizes limited most studies. Compared with data for unexposed pregnancies, fair- to good-quality prospective cohort studies reported that interferon β exposure was associated with lower mean birth weight, shorter mean birth length, and preterm birth (<37 weeks), but not low birth weight (<2,500 g), cesarean delivery, congenital anomaly (including malformation), or spontaneous abortion. Fewer studies of fair quality were available for glatiramer acetate and natalizumab. Glatiramer acetate exposure was not associated with lower mean birth weight, congenital anomaly, preterm birth, or spontaneous abortion. Natalizumab exposure did not appear to be associated with shorter mean birth length, lower mean birth weight, or lower mean gestational age. No studies examined mitoxantrone or fingolimod exposure. One study of paternal DMD use during conception found no effect on gestational age or birth weight. Few studies examined longer-term developmental outcomes.
conclusionFurther studies are needed to determine the potential risks associated with preconceptional and in utero DMD exposure in patients with MS. Discontinuation of DMDs before conception is still recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.